Inhal Pharma Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 80

Employees

  • Latest Deal Type
  • Series C

  • Investors
  • 13

Inhal Pharma General Information

Description

Developer of a dry powder inhalation platform designed to advance formulation development, inhaler design, and inhaled drug manufacturing. The company offers integrated development capabilities, a portfolio of inhaled health products, generic dry powder inhalers, and emerging inhaled therapeutics, enabling patients with respiratory and systemic conditions to access practical and effective inhaled treatments.

Contact Information

Formerly Known As
Ningbo Inhal, Ningbo Inhal Pharmaceutical Co., Ltd., Ningbo Yihe Pharmaceutical Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Zhejiang Provincial New Materials Industry Innovation Complex
  • Number 2660 Yongjiang Avenue
  • Ningbo City, Zhejiang
  • China
+86 0574
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Zhejiang Provincial New Materials Industry Innovation Complex
  • Number 2660 Yongjiang Avenue
  • Ningbo City, Zhejiang
  • China
+86 0574

Inhal Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inhal Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C) 12-Mar-2026 Completed Generating Revenue
11. Later Stage VC (Series B) 31-Dec-2025 Completed Generating Revenue
10. Later Stage VC (Series A2) 26-Nov-2025 Completed Generating Revenue
9. Later Stage VC 04-Jul-2025 Completed Generating Revenue
8. Early Stage VC (Series A1) 12-Mar-2025 Completed Generating Revenue
7. Secondary Transaction - Private 08-Jul-2024 Completed Generating Revenue
6. Secondary Transaction - Private 26-Apr-2024 Completed Generating Revenue
5. Early Stage VC 23-Feb-2024 Completed Generating Revenue
4. Early Stage VC (Series A) 16-Oct-2023 $6.88M $8.41M Completed Generating Revenue
3. Secondary Transaction - Private 18-Sep-2023 $1.53M Completed Generating Revenue
To view Inhal Pharma’s complete valuation and funding history, request access »

Inhal Pharma Patents

Inhal Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026099766-A1 Continuous capsule inhalation device Pending 06-Nov-2024
EP-4714433-A1 Inhalation formulation for treating ipf disease and preparation method therefor Pending 07-Sep-2023
US-20260083702-A1 Inhalation formulation for treating ipf disease and preparation method therefor Pending 07-Sep-2023
WO-2025051276-A1 Inhalation formulation for treating ipf disease and preparation method therefor Inactive 07-Sep-2023
US-11980859-B2 Powder rotary fluidization device and method thereof Active 25-Aug-2022 B01F33/405
To view Inhal Pharma’s complete patent history, request access »

Inhal Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inhal Pharma Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing State-owned Capital Operation and Management Government Minority
Sunz Fund Venture Capital Minority
Beijing Shunxi Private Equity Fund Management Growth/Expansion Minority
CBC Group (Singapore) PE/Buyout Minority
Zhangzhou Pien Tze Huang Investment Management PE-Backed Company Minority
You’re viewing 5 of 13 investors. Get the full list »

Inhal Pharma FAQs

  • When was Inhal Pharma founded?

    Inhal Pharma was founded in 2020.

  • Where is Inhal Pharma headquartered?

    Inhal Pharma is headquartered in Ningbo City, China.

  • What is the size of Inhal Pharma?

    Inhal Pharma has 80 total employees.

  • What industry is Inhal Pharma in?

    Inhal Pharma’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Inhal Pharma a private or public company?

    Inhal Pharma is a Private company.

  • What is Inhal Pharma’s current revenue?

    The current revenue for Inhal Pharma is .

  • How much funding has Inhal Pharma raised over time?

    Inhal Pharma has raised $29.5M.

  • Who are Inhal Pharma’s investors?

    Beijing State-owned Capital Operation and Management, Sunz Fund, Beijing Shunxi Private Equity Fund Management, CBC Group (Singapore), and Zhangzhou Pien Tze Huang Investment Management are 5 of 13 investors who have invested in Inhal Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process